Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 49

1.

Malignant tumor of prostate

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being African-American, and some genetic changes. Symptoms of prostate cancer may include: -Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling. -Low back pain. -Pain with ejaculation. Your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (PSA). Other tests include ultrasound, x-rays, or a biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
138169
Concept ID:
C0376358
Neoplastic Process
2.

Prostate cancer

A cancer of the prostate. [from HPO]

MedGen UID:
506673
Concept ID:
CN167851
Finding
3.

Cannabinoid

terpene constituents of Cannabis. [from CRISP]

MedGen UID:
737
Concept ID:
C0006864
Pharmacologic Substance
4.

Cannabinoid Receptor Agonists

Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. [from MeSH]

MedGen UID:
473699
Concept ID:
C2927148
Pharmacologic Substance
5.

SR141716

MedGen UID:
220811
Concept ID:
C1174273
Pharmacologic Substance
6.

agonists

Used with chemicals, drugs, and endogenous substances to indicate substances or agents that have affinity for a receptor and intrinsic activity at that receptor. (From Textbook of Pharmacology, 1991, p.16) [from MeSH]

MedGen UID:
116746
Concept ID:
C0243192
Pharmacologic Substance
7.

Adenocarcinoma

A malignant neoplasm arising from glandular cells. [from NCI]

MedGen UID:
122
Concept ID:
C0001418
Neoplastic Process
8.

PACHYONYCHIA CONGENITA 3

MedGen UID:
811523
Concept ID:
C3714948
Disease or Syndrome
9.

PC-K6a

Pachyonychia congenita (PC) is an autosomal dominant genodermatosis with the main clinical features of hypertrophic nail dystrophy, painful and highly debilitating plantar keratoderma, oral leukokeratosis, and a variety of epidermal cysts. Although the condition had previously been subdivided clinically into Jadassohn-Lewandowsky PC type 1 and Jackson-Lawler PC type 2, patients with PC were later found to have a mixed constellation of both types, leading to a classification of PC based on genotype (summary by Sybert, 2010; Eliason et al., 2012; McLean et al., 2011). For a discussion of genetic heterogeneity of pachyonychia congenita, see 167200. Historical Classification of Pachyonychia Congenita Gorlin et al. (1976) suggested that 2 distinct syndromes are subsumed under the designation pachyonychia congenita. PC type 1, the Jadassohn-Lewandowsky type, shows oral leukokeratosis. PC type 2, the Jackson-Lawler type, has natal teeth and epidermoid cysts (cylindromas), but no oral leukoplakia. Corneal dystrophy may be a feature exclusively of the Jackson-Lawler type. Smith et al. (1998) stated that PC type 2, in contrast to PC type 1, has minimal oral involvement and milder keratoderma, and multiple steatocystomas (184500) is a major clinical feature. Steatocystoma, also known as eruptive vellus cyst, is a cystic hamartoma lined by sebaceous ductal epithelium. On the basis of a study of 13 patients with PC type 1 or type 2, Terrinoni et al. (2001) concluded that the presence of pilosebaceous cysts following puberty is the best indicator of PC type 2; prepubescent patients are more difficult to classify due to the lack of cysts. Natal teeth are indicative of PC type 2, although their absence does not preclude the PC type 2 diagnosis. [from OMIM]

MedGen UID:
776873
Concept ID:
CN185878
Disease or Syndrome
10.

Cannabis

MedGen UID:
671294
Concept ID:
C0678449
Pharmacologic Substance
11.

Agonist

A drug or substance that binds to a receptor inside a cell or on its surface and causes the same action as the substance that normally binds to the receptor. [from NCI]

MedGen UID:
459858
Concept ID:
C2987634
Pharmacologic Substance
12.

Therapeutic agent

1D1; Basic Sciences Research (includes vaccine and chemotherapy development); Therapeutic Agents (antiviral, antimicrobial, immunomodulating and antineoplastic agents); Development. Physical or chemical agents that may improve the health of a patient by impeding cancer or other diseases [from NCI]

MedGen UID:
299559
Concept ID:
C1611640
Pharmacologic Substance
13.

Disease regression

Return to a former state; a subsidence of the symptoms of a disease process; in cancer, a decrease in the size of a tumor or in the extent of cancer in the body. [from NCI]

MedGen UID:
195771
Concept ID:
C0684320
Pathologic Function
14.

Proliferation

Growth and reproduction of new similar forms, e.g. cells, buds, or offspring. [from NCI]

MedGen UID:
137720
Concept ID:
C0334094
Pathologic Function
15.

Marihuana

Any part of, or extract from, the female hemp plant Cannabis sativa. Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties. This agent has potential use for treating cancer pain and cachexia. (NCI04) [from NCI]

MedGen UID:
44288
Concept ID:
C0024808
Pharmacologic Substance
16.

Androgens

A class of sex hormones associated with the development and maintenance of the secondary male sex characteristics, sperm induction, and sexual differentiation. In addition to increasing virility and libido, they also increase nitrogen and water retention and stimulate skeletal growth. (MeSH) [from NCI]

MedGen UID:
8060
Concept ID:
C0002844
Pharmacologic Substance
17.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function
18.

Male Urogenital Diseases

Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE). [from MeSH]

MedGen UID:
318601
Concept ID:
C1720894
Disease or Syndrome
19.

Membrane Transport Modulators

Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS. [from MeSH]

MedGen UID:
288786
Concept ID:
C1563710
Pharmacologic Substance
20.

Epithelial Neoplasm

neoplasm of epithelial origin, ranging from benign (adenoma and papilloma) to malignant (carcinoma). [from CRISP]

MedGen UID:
277963
Concept ID:
C1368683
Neoplastic Process

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...